XML 84 R72.htm IDEA: XBRL DOCUMENT v3.21.4
BUSINESS COMBINATIONS - Unaudited pro forma (Details) - USD ($)
$ in Thousands
12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
BUSINESS COMBINATIONS    
Total revenues $ 104,084 $ 81,739
Net income (loss) 8,741 335
Income tax benefit 4,776 (147)
Pre-Clinical Research Services, Inc.    
BUSINESS COMBINATIONS    
Transaction costs 248  
HistoTox Labs    
BUSINESS COMBINATIONS    
Transaction costs 576  
Bolder BioPATH    
BUSINESS COMBINATIONS    
Transaction costs 584  
Income tax benefit and other expenses   4,867
Income tax benefit 4,867  
HistoTox Labs and Bolder BioPATH combined    
BUSINESS COMBINATIONS    
Transaction costs   $ 1,128
Incremental interest expense and amortizaiton of deferred financing costs $ 302  
HistoTox Labs and Bolder BioPATH combined | Minimum    
BUSINESS COMBINATIONS    
Weighted-average estimated useful life 6 years  
HistoTox Labs and Bolder BioPATH combined | Maximum    
BUSINESS COMBINATIONS    
Weighted-average estimated useful life 8 years